Title: Correlation between PSA response and response assessment with 68Ga-PSMA-11 PET/CT-derived metabolic parameters in patients treated with 225Ac-PSMA-617 for metastatic prostate carcinoma
Authors: LAWAL IMORGENSTERN ALFREDKNOESEN OTTOVORSTER MARIZAPOPOOLA GOMAHAPANE JOHNCYLENGANA TBOSHOMANE TMOKOALA KBRUCHERTSEIFER FRANKSATHEKGE MIKE
Citation: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 46 no. S1 p. S645
Publisher: SPRINGER
Publication Year: 2019
JRC N°: JRC116618
ISSN: 1619-7070 (online)
URI: https://publications.jrc.ec.europa.eu/repository/handle/JRC116618
DOI: 10.1007/s00259-019-04486-2
Type: Articles in periodicals and books
Abstract: PSA decline ≥50% is the validated criteria for assessing response to treatment in patients with prostate carcinoma. 68Ga-PSMA-11 PET/CT-derived metabolic parameters such as SUVmax, SUVmean, whole-body tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA) are increasingly being reported as metrics for response assessment. We herein compare the response assessment using PSA decline versus 68Ga-PSMA-11 PET/CT-derived metabolic parameters in patients treated with 225Ac-PSMA-617 for metastatic castration-resistant prostate carcinoma (mCRPC).
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.